Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from ...

AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...

SAN DIEGO -- Adding amikacin liposome inhalation suspension (ALIS; Arikayce) to a macrolide-based regimen appeared to reduce respiratory symptoms and improve culture conversion rates in patients with ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of patients reported improvements to quality of life compared with placebo. Nontuberculous ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Accurate detection is essential to prevent misdiagnosis and ensure the right treatment, particularly in cases involving drug-resistant TB or NTM infections. The Hi-PCR ® MTB/NTM Probe PCR Kit offers a ...

Avian tuberculosis, also known as mycobacterium avium complex (MAC) or MAC lung disease, is a respiratory illness. It can lead to symptoms such as chronic cough, shortness of breath, and weight loss.

Shares of Insmed INSM gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025.

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...